Asia: +65-6223-2436
Int'l: +1-860-674-8796
US: +1-866-353-3335
  • Japanese
  • Korean
  • Chinese
Cover Image

Inhaled Drug Delivery: Devices, Indications, Therapeutics, Markets and Forecasts

Greystone Research Associates is pleased to announce the publication of a new market study. Inhaled Drug Delivery: Devices, Indications, Therapeutics, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for inhaled drug delivery. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

User-friendly Administration for a Diverse and Growing Therapeutic Need

Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary delivery of systemic drug therapies is focused on chronic diseases and refractory conditions - aliments that require frequent drug administration for a protracted period of time.

The role of device design and development in defining and driving emerging opportunities in this sector cannot be overstated. Nebulizers, metered dose inhalers (MDIs), and dry powder inhalers (DPIs) have each found a niche in the quest for optimal treatment and convenient use. While nebulizers have evolved relatively independently of the drug formulations they deliver, the current generation of MDIs and DPIs have been developed or tailored for the specific pharmaceutical being delivered, resulting in improved performance.

Report Value Matrix


  • Analyzes and evaluates inhaled drugs currently in development and assesses the market potential for existing and probable future products
  • Examines inhalation device technology for commercial and development-stage devices, and evaluates product technology issues and evolving market factors
  • Provides detailed assessments of targeted disease segments, forecast growth and market potential, and therapeutic options
  • Forecasts the impact of new and emerging inhaled drug therapeutics on healthcare markets and prescribing decisions to 2016

Table of Contents

  • Executive Summary
  • Inhaled Drug Market Dynamics
  • Therapeutic Targets
  • Demographics and Growth
  • Competing Technologies
  • Market Drivers
  • Factors Limiting Growth
  • Inhalation Technology & Product
    • Development Factors
  • Drug Formulations
  • Formulation Technologies
  • Excipients and Release Profiles
  • Inhalation Device Design Factors
  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers
  • Performance Factors
  • Bioavailability
  • Dose Reproducibility
  • Active Compound Stability
  • Combination Drug Inhalers
  • Testing and Packaging
  • Emerging Device Technologies
  • Inhalation Devices - Device
    • Assessments and Product Strategies
  • Dry Powder inhalers
  • Commercial Devices
  • Development-stage DPI Devices
  • Metered Dose Inhalers
  • Nebulizers
  • Compressed Air Nebulizers
  • Ultrasonic Nebulizers
  • Advanced Technology Nebulizers
  • Inhaled Drugs - Therapeutic Segment
    • Analysis & Forecasts
  • Upper Respiratory Indications
  • Asthma/COPD
  • Allergic Rhinitis
  • Systemic Drug Delivery
  • Anaphylaxis
  • Bioterror
  • Cardiovascular Medicine
  • Diabetes
  • Hereditary Diseases
  • Immunology
  • Infectious Diseases
  • Osteoporosis
  • Neurology
  • Oncology
  • Pain Management
  • Sexual Health
  • Market Factors
  • Device Packaging
  • Regulatory Issues
  • Patient Compliance
  • The Role of CMOs/CSOs
  • Healthcare Economics
  • Market Sector Company Profiles
Show More